

Philip L Mccarthy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6978029/publications.pdf>

Version: 2024-02-01

127
papers

4,682
citations

218677

26
h-index

110387

64
g-index

128
all docs

128
docs citations

128
times ranked

6013
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1 | Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma. <i>Nature Communications</i> , 2022, 13, 807. | 12.8 | 29 |
| 2 | A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022. <i>Expert Review of Anticancer Therapy</i> , 2022, , 1-13. | 2.4 | 3 |
| 3 | Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damage. <i>British Journal of Haematology</i> , 2022, 199, 65-75. | 2.5 | 8 |
| 4 | Immune cell differences between patients in different stages of monoclonal plasma cell disorders.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8065-8065. | 1.6 | 1 |
| 5 | Lenalidomide, bortezomib, and dexamethasone (Rvd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA4-LBA4. | 1.6 | 3 |
| 6 | Serological Response to Vaccination after Autologous Transplantation for Multiple Myeloma Is Associated with Improved Progression-Free and Overall Survival. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 245.e1-245.e8. | 1.2 | 4 |
| 7 | Comparing thermal stress reduction strategies that influence MDSC accumulation in tumor bearing mice. <i>Cellular Immunology</i> , 2021, 361, 104285. | 3.0 | 12 |
| 8 | Melflufen: A Next-Generation Nitrogen Mustard. <i>Journal of Clinical Oncology</i> , 2021, 39, 836-839. | 1.6 | 3 |
| 9 | Optical Coherence Tomography for Quantifying Human Cutaneous Chronic Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 271.e1-271.e8. | 1.2 | 2 |
| 10 | Future Directions in Maintenance Therapy in Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2021, 10, 2261. | 2.4 | 8 |
| 11 | Genome-Wide Association Analyses Identify Variants in IRF4 Associated With Acute Myeloid Leukemia and Myelodysplastic Syndrome Susceptibility. <i>Frontiers in Genetics</i> , 2021, 12, 554948. | 2.3 | 8 |
| 12 | Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemia. <i>Scientific Reports</i> , 2021, 11, 15004. | 3.3 | 4 |
| 13 | Novel genetic variants associated with mortality after unrelated donor allogeneic hematopoietic cell transplantation. <i>EClinicalMedicine</i> , 2021, 40, 101093. | 7.1 | 8 |
| 14 | A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). <i>American Journal of Hematology</i> , 2021, 96, 1595-1603. | 4.1 | 15 |
| 15 | The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 807-816. | 1.2 | 3 |
| 16 | Replicated Risk Index of Patient Functional Status Prior to Allogeneic Hematopoietic Cell Transplantation Predicts Healthcare Utilization and Survival. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 875.e1-875.e9. | 1.2 | 1 |
| 17 | Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients post-unrelated HCT. <i>Blood Advances</i> , 2021, 5, 66-70. | 5.2 | 6 |
| 18 | β2-adrenergic receptor signaling regulates metabolic pathways critical to myeloid-derived suppressor cell function within the TME. <i>Cell Reports</i> , 2021, 37, 109883. | 6.4 | 45 |

| # | ARTICLE | IF | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Prediction of Malignant Cell Infiltration Patterns with Texture Features of Biopsy-Correlated Positron Emission Tomography of Osteolytic Lesions in Multiple Myeloma. <i>Blood</i> , 2021, 138, 3997-3997. | 1.4 | 0 |
| 20 | Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT) Tj ETQq0 0 0.4 BT /Overlock 10 T | 1.4 | 0 |
| 21 | Clinical Significance of Spatial Heterogeneity in Newly Diagnosed and Relapsed Multiple Myeloma. <i>Blood</i> , 2021, 138, 1607-1607. | 1.4 | 0 |
| 22 | Age, Sex and Self-Reported Race Differences in Immune Profiles of Hematologic Malignancy Patients. <i>Blood</i> , 2021, 138, 4066-4066. | 1.4 | 0 |
| 23 | Low Intensity Alternative Induction Therapy for Acute Myeloid Leukemia (AML). Real World Experience from Tawam Hospital, United Arab Emirates. <i>Blood</i> , 2021, 138, 4409-4409. | 1.4 | 0 |
| 24 | Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 77-85. | 2.4 | 4 |
| 25 | Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e7-e15. | 2.0 | 16 |
| 26 | Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 161-173. | 1.5 | 20 |
| 27 | Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell-Associated Encephalopathy (ICE) Score. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e271-e274. | 2.0 | 13 |
| 28 | Low-Level Cytomegalovirus Antigenemia Promotes Protective Cytomegalovirus Antigen-Specific T Cells after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2147-2154. | 2.0 | 4 |
| 29 | Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e247-e255. | 2.0 | 5 |
| 30 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511. | | 138 |
| 31 | β2-Adrenergic receptor activation on donor cells ameliorates acute GvHD. <i>JCI Insight</i> , 2020, 5, . | 5.0 | 13 |
| 32 | Spatiotemporal Assessment of Immunogenomic Heterogeneity in Multiple Myeloma. <i>Blood</i> , 2020, 136, 14-15. | 1.4 | 2 |
| 33 | Diffuse Large B Cell Lymphoma and Programmed Death-Ligand 1 Expression. a Clinical and Pathological Study of Patients Seen in Tawam Hospital UAE. <i>Blood</i> , 2020, 136, 26-27. | 1.4 | 0 |
| 34 | Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents. <i>Bone Marrow Transplantation</i> , 2019, 54, 497-507. | 2.4 | 11 |
| 35 | The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 889-898. | 2.4 | 6 |
| 36 | Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 31-38. | 2.3 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 39-46. | 2.3 | 5 |
| 38 | Validation of genetic associations with acute GVHD and nonrelapse mortality in DISCOVeRY-BMT. <i>Blood Advances</i> , 2019, 3, 2337-2341. | 5.2 | 8 |
| 39 | Multiple functional variants in the IL1RL1 region are pretransplant markers for risk of GVHD and infection deaths. <i>Blood Advances</i> , 2019, 3, 2512-2524. | 5.2 | 7 |
| 40 | Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e89-e97. | 2.0 | 12 |
| 41 | Commentary on "œs posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma" by Giovanni Barosi and Robert Peter Gale. <i>Leukemia</i> , 2019, 33, 565-566. | 7.2 | 2 |
| 42 | Reduced-Intensity Conditioning with Fludarabine, Melphalan, and Total Body Irradiation for Allogeneic Hematopoietic Cell Transplantation: The Effect of Increasing Melphalan Dose on Underlying Disease and Toxicity. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 689-698. | 2.0 | 9 |
| 43 | Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 599-605. | 2.0 | 20 |
| 44 | Î2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells. <i>Journal of Clinical Investigation</i> , 2019, 129, 5537-5552. | 8.2 | 141 |
| 45 | Î2- Adrenergic Signaling Regulates Graft Versus Host Disease after Allogeneic Transplantation While Preserving Graft Versus Leukemia Effect. <i>Blood</i> , 2019, 134, 1915-1915. | 1.4 | 3 |
| 46 | Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550). <i>Blood</i> , 2019, 134, 4451-4451. | 1.4 | 5 |
| 47 | Impact of conditioning regimen on peripheral blood hematopoietic cell transplant. <i>World Journal of Clinical Oncology</i> , 2019, 10, 86-97. | 2.3 | 0 |
| 48 | De Novo and Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome: Similarities and Differences in SNP-Array Detected Chromosomal Aberrations in Pre-Transplant Blood Samples. <i>Blood</i> , 2019, 134, 1430-1430. | 1.4 | 2 |
| 49 | Genome Wide Interaction Analysis Identifies Expression Quantitative Trait Loci Associated with Reduced Survival after Reduced Intensity Conditioning HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant. <i>Blood</i> , 2019, 134, 4595-4595. | 1.4 | 0 |
| 50 | The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1322-1340. | 2.0 | 85 |
| 51 | Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation. <i>Blood</i> , 2018, 131, 2490-2499. | 1.4 | 21 |
| 52 | Serine protease inhibitor 6 protects alloreactive T cells from Granzyme B-mediated mitochondrial damage without affecting graft-versus-tumor effect. <i>Oncolmmunology</i> , 2018, 7, e1397247. | 4.6 | 11 |
| 53 | Blockade of Host Î2-Adrenergic Receptor Enhances Graft-versus-Tumor Effect through Modulating APCs. <i>Journal of Immunology</i> , 2018, 200, 2479-2488. | 0.8 | 17 |
| 54 | BPX-501 T cells interfere with minimal residual disease evaluation of B-cell acute lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 2018, 53, 651-653. | 2.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 55 | BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 641-648. | 2.0 | 19 |
| 56 | Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase. <i>Journal of Clinical Oncology</i> , 2018, 36, 2101-2104. | 1.6 | 8 |
| 57 | Host-Derived Serine Protease Inhibitor 6 Provides Granzyme B-Independent Protection of Intestinal Epithelial Cells in Murine Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2397-2408. | 2.0 | 8 |
| 58 | Update on the role of lenalidomide in patients with multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 175-190. | 2.5 | 42 |
| 59 | Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389. | 7.1 | 67 |
| 60 | Multiple Functional Donor Polymorphisms in IL1RL1 region Associate with Death Due to GvHD or Infection after Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for AML and MDS. <i>Blood</i> , 2018, 132, 312-312. | 1.4 | 0 |
| 61 | Multiple Myeloma Therapy in Tawam Hospital. First Report from United Arab Emirates (UAE). <i>Blood</i> , 2018, 132, 5652-5652. | 1.4 | 1 |
| 62 | Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. <i>Drugs</i> , 2017, 77, 505-520. | 10.9 | 150 |
| 63 | Host-Derived CD70 Suppresses Murine Graft-versus-Host Disease by Limiting Donor T Cell Expansion and Effector Function. <i>Journal of Immunology</i> , 2017, 199, 336-347. | 0.8 | 11 |
| 64 | Ascertainment of Unmet Needs and Participation in Health Maintenance and Screening of Adult Hematopoietic Cell Transplantation Survivors Followed in a Formal Survivorship Program. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1968-1973. | 2.0 | 14 |
| 65 | T Cell-Derived CD70 Delivers an Immune Checkpoint Function in Inflammatory T Cell Responses. <i>Journal of Immunology</i> , 2017, 199, 3700-3710. | 0.8 | 34 |
| 66 | Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant. <i>Blood</i> , 2017, 130, 1585-1596. | 1.4 | 45 |
| 67 | Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. <i>Blood</i> , 2017, 130, 1156-1164. | 1.4 | 210 |
| 68 | Quantifying MHC dextramer-induced NFAT activation in antigen-specific T cells as a functional response parameter. <i>Methods</i> , 2017, 112, 75-83. | 3.8 | 5 |
| 69 | Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHST. <i>Blood Advances</i> , 2017, 1, 1056-1066. | 5.2 | 40 |
| 70 | Genetic association with B-cell acute lymphoblastic leukemia in allogeneic transplant patients differs by age and sex. <i>Blood Advances</i> , 2017, 1, 1717-1728. | 5.2 | 15 |
| 71 | Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 3279-3289. | 1.6 | 535 |
| 72 | Interview with Dr Philip McCarthy. <i>International Journal of Hematologic Oncology</i> , 2017, 6, 97-99. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 73 | The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. <i>Haematologica</i> , 2016, 101, 1426-1433. | 3.5 | 53 |
| 74 | Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. <i>Blood</i> , 2016, 128, 2450-2456. | 1.4 | 32 |
| 75 | Role of stem cell transplant and maintenance therapy in plasma cell disorders. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 504-511. | 2.5 | 22 |
| 76 | Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1493-1503. | 2.0 | 55 |
| 77 | Discontinuation of Systematic Surveillance and Contact Precautions for Vancomycin-Resistant <i>Enterococcus</i> (VRE) and Its Impact on the Incidence of VRE <i>faecium</i> Bacteremia in Patients with Hematologic Malignancies. <i>Infection Control and Hospital Epidemiology</i> . 2016. 37. 398-403. | 1.8 | 40 |
| 78 | Evolution of Multiparametric Flow Cytometry Testing for Minimal Residual Disease Assessment in Multiple Myeloma and Its Impact on Clinical Outcomes: A Single Institution Experience. <i>Blood</i> , 2016, 128, 2274-2274. | 1.4 | 1 |
| 79 | Replication of Candidate SNP Survival Analyses and Gene-Based Tests of Association with Survival Outcomes after an Unrelated Donor Blood or Marrow Transplant: Results from the Discovery-BMT Study. <i>Blood</i> , 2016, 128, 71-71. | 1.4 | 0 |
| 80 | Exome Array Analyses Identify New Genes Influencing Survival Outcomes after HLA-Matched Unrelated Donor Blood and Marrow Transplantation. <i>Blood</i> , 2016, 128, 518-518. | 1.4 | 0 |
| 81 | Identification of Immune Phenotypes Associated with Improved Progression Free and Overall Survival for Patients with Multiple Myeloma Treated with Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 3454-3454. | 1.4 | 0 |
| 82 | Exome Array Analyses Identify Low-Frequency Germline Variants Associated with Increased Risk of AML in a HLA-Matched Unrelated Donor Blood and Marrow Transplant Population. <i>Blood</i> , 2016, 128, 42-42. | 1.4 | 0 |
| 83 | Granzyme B Contributes to the Optimal Graft-Versus-Tumor Effect Mediated by Conventional CD4 T Cells. <i>Journal of Immunology Research and Therapy</i> , 2016, 1, 22-28. | 1.0 | 7 |
| 84 | Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074. | 1.4 | 586 |
| 85 | Continued role for ASCT in multiple myeloma. <i>Lancet Oncology</i> , The, 2015, 16, 1571-1573. | 10.7 | 0 |
| 86 | Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 793-798. | 2.0 | 23 |
| 87 | Identification and Utilization of Donor and Recipient Genetic Variants to Predict Survival After HCT: Are We Ready for Primetime?. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 45-58. | 2.3 | 11 |
| 88 | The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1251-1257. | 2.0 | 14 |
| 89 | Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1479-1487. | 2.0 | 173 |
| 90 | Population-Based Analysis of Hematologic Malignancy Referrals to a Comprehensive Cancer Center, Referrals for Blood and Marrow Transplantation, and Participation in Clinical Trial, Survey, and Biospecimen Research by Race. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1488-1494. | 2.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 91 | Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1046-1053. | 2.0 | 133 |
| 92 | Granzyme B-Mediated Activation-Induced Death of CD4+ T Cells Inhibits Murine Acute Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2015, 195, 4514-4523. | 0.8 | 21 |
| 93 | Housing Temperature-Induced Stress Is Suppressing Murine Graft-versus-Host Disease through β 2-Adrenergic Receptor Signaling. <i>Journal of Immunology</i> , 2015, 195, 5045-5054. | 0.8 | 48 |
| 94 | Establishment of Definitions and Review Process for Consistent Adjudication of Cause-specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1679-1686. | 2.0 | 37 |
| 95 | Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 266-274. | 2.0 | 331 |
| 96 | Long-Term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 55-59. | 2.0 | 34 |
| 97 | Effect of Immune Reconstitution on Survival after Autologous Hematopoietic Cell Transplant for B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 3173-3173. | 1.4 | 1 |
| 98 | Combined Donor and Recipient Non-HLA Genotypes Show Evidence of Genome Wide Association with Transplant Related Mortality (TRM) after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (URD-BMT) (DISCOVeRY-BMT study). <i>Blood</i> , 2015, 126, 61-61. | 1.4 | 7 |
| 99 | Evidence for Heterogeneous Genetic Associations with Acute Lymphoblastic Leukemia (ALL) By Cytogenetics and Sex in High-Risk Patients Treated with Matched Unrelated Donor Allogeneic Blood or Marrow Transplant (URD-BMT). <i>Blood</i> , 2015, 126, 2621-2621. | 1.4 | 5 |
| 100 | Genome-Wide Association Study of Overall and Progression-Free Survival after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT study). <i>Blood</i> , 2015, 126, 397-397. | 1.4 | 1 |
| 101 | Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 1113-1129. | 2.2 | 4 |
| 102 | Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 333-342. | 10.7 | 256 |
| 103 | Second transplant as a standard for multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, 786-788. | 10.7 | 2 |
| 104 | Maintenance Therapy for Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 839-859. | 2.2 | 14 |
| 105 | Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1369-1374. | 2.0 | 5 |
| 106 | Dextramer reagents are effective tools for quantifying CMV antigen-specific T cells from peripheral blood samples. , 2014, , n/a-n/a. | | 8 |
| 107 | Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1116-1123. | 2.0 | 104 |
| 108 | Where Are We Going with Autologous Transplantation for Multiple Myeloma?. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1532-1533. | 2.0 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 109 | Granzyme B-Mediated Damage of CD8+ T Cells Impairs Graft-versus-Tumor Effect. <i>Journal of Immunology</i> , 2013, 190, 1341-1350. | 0.8 | 21 |
| 110 | Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 496-503. | 2.5 | 26 |
| 111 | Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 496-503. | 2.5 | 6 |
| 112 | Perforin Is Important For Both CD4+ and CD8+ T Cell-Mediated Graft-Versus-Tumor Effect But Plays Differential Roles In CD4+ and CD8+ T Cell Expansion After Allogeneic Transplantation. <i>Blood</i> , 2013, 122, 3255-3255. | 1.4 | 0 |
| 113 | Analysis Of Immune Cell Populations Before and After Autologous Hematopoietic Stem Cell Transplant For Multiple Myeloma: Association With Early Recovery Of Absolute Lymphocyte Count and Progression-Free Survival. <i>Blood</i> , 2013, 122, 3348-3348. | 1.4 | 0 |
| 114 | Housing Mice At Sub-Thermoneutral Temperatures Influences Severity Of Gvhd In Mouse Models. <i>Blood</i> , 2013, 122, 5422-5422. | 1.4 | 0 |
| 115 | A TLR5 Agonist Enhances CD8+T Cell-Mediated Graft-versus-Tumor Effect without Exacerbating Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2012, 189, 4719-4727. | 0.8 | 25 |
| 116 | Short Course of Levofloxacin During Neutropenia Prevents Early and Late Bacteremia Episodes After Allogeneic Blood and Marrow Transplantation (alloBMT). <i>Blood</i> , 2012, 120, 4141-4141. | 1.4 | 0 |
| 117 | A CIBMTR Prognostic Model for Progression-Free Survival (PFS) After Autologous Hematopoietic Cell Transplantation (AHCT) for Relapsed or Refractory Hodgkin Lymphoma (HL). <i>Blood</i> , 2011, 118, 499-499. | 1.4 | 14 |
| 118 | Fludarabine, Melphalan and Low Dose Total Body Irradiation for Reduced Intensity Conditioning (RIC) Prior to Allogeneic Hematopoietic Cell Transplantation (AlloHCT). <i>Blood</i> , 2011, 118, 4570-4570. | 1.4 | 0 |
| 119 | Micro Dose Methotrexate (MTX) Is Equivalent to Full Dose MTX and Superior to No MTX for Acute Graft-Versus-Host Disease Prophylaxis. <i>Blood</i> , 2011, 118, 3038-3038. | 1.4 | 0 |
| 120 | Optimizing the Timing of Allogeneic Blood or Marrow Transplantation (BMT) in a Prospective Cohort of Relapsed or Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2011, 118, 3096-3096. | 1.4 | 4 |
| 121 | Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events.. <i>Blood</i> , 2009, 114, 3416-3416. | 1.4 | 8 |
| 122 | Effect of Bone Marrow Hypoplasia Secondary to Reinduction Therapy for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) on Outcomes after Blood and Marrow Transplantation (BMT).. <i>Blood</i> , 2006, 108, 3033-3033. | 1.4 | 0 |
| 123 | High Frequency and Early Onset of Bone Mineral Density Loss Following Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 2011-2011. | 1.4 | 6 |
| 124 | Histopathologic verification of acute leukemia (AL) in a cohort of 463 post-Chernobyl patients from Belarus, Russia and Ukraine. <i>Leukemia Research</i> , 2004, 28, 1273-1280. | 0.8 | 5 |
| 125 | VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) Is an Effective Initial Therapy with High Response Rates for Patients with Treatment Naïve Multiple Myeloma (MM).. <i>Blood</i> , 2004, 104, 3463-3463. | 1.4 | 14 |
| 126 | Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. <i>Blood</i> , 2002, 100, 406-414. | 1.4 | 503 |

| # | ARTICLE | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 127 | Gaucher's disease and chronic lymphocytic leukemia. Possible pathogenetic link between Gaucher's disease and b-cell proliferations?. <i>Cancer</i> , 1984, 54, 312-314. | 4.1 | 49 |